Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 53 от 100

Набира участници Фаза 1/2

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer Pancreatic Ductal Adenocarcinoma

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Начало: 14.11.2023 Край: 01.06.2029 Възраст: от 18 г.

France, Germany, Italy +4 Revolution Medicines, Inc. NCT06128551

Набира участници

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Infertility, Male Cancer Autoimmune Disorder

Spermatogonial stem cell transplantation through ultrasound guided rete testis injection and testicular tissue grafting will be performed for participants who have frozen testicular tissue prior to gonadotoxic therapy. The purpose of this study is to test the safety and feasibility of these transplant technologies and restore fertility for these participants.

Начало: 10.11.2023 Край: 31.05.2030

United States University of Pittsburgh NCT04452305

Набира участници

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Breast Cancer

This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.

Начало: 02.11.2023 Край: 01.11.2035 Възраст: от 18 г.

Spain, Switzerland, United States ARTIDIS AG NCT06085833

Набира участници

Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial

Metastatic Cancer

This is a phase II/III international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.

Начало: 16.10.2023 Край: 01.01.2034 Възраст: от 18 г.

Canada, Switzerland London Health Sciences Centre Research Institute OR Law NCT05508464

Набира участници Фаза 1

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Triple Negative Breast Cancer Diffuse Large B Cell Lymphoma Follicular Lymphoma Lymphoma, Non-Hodgkin +10

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Начало: 13.10.2023 Край: 29.08.2026 Възраст: от 18 г. Лечение

Australia, United States OncoNano Medicine, Inc. NCT06022029

Набира участници

PRostate Olaparib Real World Evidence Study

Metastatic Castration-resistant Prostate Cancer

This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.

Начало: 11.10.2023 Край: 13.10.2028 Възраст: от 18 г.

France AstraZeneca NCT06031805

Набира участници

Cold Snare Endoscopic Mucosal Resection (EMR) vs Cold EMR With Margin Snare Tip Soft Coagulation (STSC)

Colorectal Polyp Colon Adenoma Colon Cancer

Randomised controlled trial comparing cold snare endoscopic mucosal resection (EMR) with cold snare EMR and adjuvant margin STSC in the complete resection of 15-40mm lateral-spreading adenomas

Начало: 19.09.2023 Край: 01.10.2028 Възраст: от 18 г. Лечение

Australia Western Sydney Local Health District NCT05041478

Набира участници Фаза 1

IKS014 in Advanced Solid Tumors That Express HER2

Breast Cancer Gastric Cancer Gastroesophageal-junction Cancer

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

Начало: 14.09.2023 Край: 01.09.2027 Възраст: от 18 г. Лечение

Australia, New Zealand, Singapore +1 Iksuda Therapeutics Ltd. NCT05872295

Набира участници Фаза 1/2

Study of AVZO-021 in Patients With Advanced Solid Tumors

Advanced Solid Tumor HR+/HER2- Breast Cancer HR+, HER2-, Advanced Breast Cancer CCNE1 Amplification +5

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Начало: 30.08.2023 Край: 31.01.2030 Възраст: от 18 г. Лечение

Australia, United States Avenzo Therapeutics, Inc. NCT05867251

Набира участници Фаза 1/2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC) Pancreatic Adenocarcinoma Non-small Cell Lung Cancer (NSCLC) Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC) +2

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Начало: 06.07.2023 Край: 01.05.2028 Възраст: от 18 г.

Belgium, United Kingdom, United States Exscientia AI Ltd., a wholly owned subsidiary of Recurs NCT05985655

Набира участници

Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging

Lung Cancer

This trial will investigate the feasibility of the Markerless Tumour Tracking technology.

Начало: 24.05.2023 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia University of Sydney NCT04086082

Набира участници Фаза 1/2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer Colorectal Cancer Solid Tumor Locally Advanced Solid Tumor +11

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Начало: 23.05.2023 Край: 31.08.2027 Възраст: от 18 г.

United States Parabilis Medicines, Inc. NCT05919264

Набира участници Фаза 3

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Endometrial Cancer

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

Начало: 18.04.2023 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +14 Karyopharm Therapeutics Inc NCT05611931

Набира участници

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

Cancer of Stomach Oesophageal Cancer Gastric Cancer Gastric Adenocarcinoma +5

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

Начало: 14.03.2023 Край: 14.09.2028 Възраст: от 18 г.

Australia Western Sydney Local Health District NCT05804331

Набира участници

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Arrhythmias, Cardiac Breast Cancer Prostatic Cancer Brain Cancer +5

This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

Начало: 28.02.2023 Край: 31.01.2026 Възраст: от 18 г.

Australia University of Sydney NCT05184790

Набира участници

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Hematologic Malignancy Blood Cancer Lymphoma Leukemia +1

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.

Начало: 30.12.2022 Край: 01.04.2027 Възраст: от 18 г.

United States Massachusetts General Hospital NCT05646576

Набира участници Фаза 1

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Advanced Cancer Metastatic Cancer Solid Tumor

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.

Начало: 10.10.2022 Край: 01.04.2028 Възраст: от 18 г.

United States Jazz Pharmaceuticals NCT05557045

Набира участници Фаза 1

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Colorectal Cancer

The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2) Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program

Начало: 04.08.2022 Край: 23.10.2026 Възраст: от 18 г.

Canada, Japan, South Korea +2 EMD Serono Research & Development Institute, Inc. NCT05464030

Набира участници Фаза 3

Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial

Breast Cancer Breast Cancer Female Breast Conserving Surgery Mastectomy

The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.

Начало: 27.07.2022 Край: 01.07.2028 Възраст: от 18 г. Превенция

Australia, Hong Kong, New Zealand +1 Monash University NCT05072314

Набира участници Фаза 2

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma of the Head and Neck Head and Neck Cancer

Cutaneous Squamous Cell Carcinoma (cSCC) is typically associated with a high tumour mutation burden, with the majority caused by Ultraviolet (UV) exposure (Pickering et al., 2014). The use of this trial using neoadjuvant Pembrolizumab in patients with cSCC who will otherwise undergo highly morbid radical surgical resection has multiple potential advantages, including: 1. Reduction in surgical and radiotherapy morbidity by reducing tumour burden and allowing the appropriate selection of patients to undergo post-operative radiotherapy; 2. Provision of immediate information about pathological response and 3. Access to tissue to provide insight into resistance mechanisms and identification of biomarkers of response. The Investigators hypothesized that the use of neoadjuvant Pembrolizumab could reduce tumour burden allowing appropriate selection of patients undergoing radical surgical resection and adjuvant radiotherapy.

Начало: 28.06.2022 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia Queensland Health NCT05025813

1 … 51 52 53 54 55 … 100